A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants
Status:
Completed
Trial end date:
2016-09-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (0.5 mg or 1
mg/day) as an add-on to levodopa in Japanese participants with Parkinson's disease with
wearing-off phenomenon.